BIOMMUNE TECHNOLOGIES INC. (formerly MC PARTNERS INC.)

Condensed Consolidated Interim Financial Statements
For the Three and Nine Months Ended August 31, 2013 and 2012

(Expressed in Canadian Dollars)
Unaudited – Prepared by management

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDTED INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed consolidated interim financial statements, they must be accompanied by a notice indicating that the condensed consolidated interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements of BIOMMUNE TECHNOLOGIES INC. (the "Company") have been prepared by management and approved by the Audit Committee and the Board of Directors of the Company.

The Company's independent auditors have not performed a review of these condensed consolidated interim financial statements in accordance with the standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity's auditors.

"*Judi Dalling*"
………………………………………
Judi Dalling
Chief Financial Officer
October 25, 2013

bioMmune Technologies Inc. (formerly MC Partners Inc.)
Condensed Consolidated Interim Statements of Financial Position
(Expressed in Canadian Dollars - unaudited)

	Notes	August 31 2013	November 30, 2012
ASSETS		**$**	**$**
Current			
Cash and cash equivalents		25,240	417,794
Short-term investment	4	1,336,590	-
HST/GST receivable		16,484	-
Prepaid expenses		10,904	-
Total current assets		1,389,218	417,794
Non-current assets			
Computer equipment and software net		1,673	-
Intangible assets	6	1,172,516	-
Total assets		2,563,407	417,794
LIABILITIES			
Current liabilities			
Accounts payable and accrued liabilities		162,698	24,085
Total liabilities		162,698	24,085
EQUITY			
Equity attributable to shareholders			
Share capital	7 b)	2,670,168	437,406
Reserves	7 d)	328,894	62,835
Accumulated deficit		(598,353)	(106,532)
Total equity		2,400,709	393,709
Total liabilities and equity		2,563,407	417,794

Approved on behalf of the Board:

"Robin Hutchison"

Director

"J. Michael Hutchison"

Director

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

bioMmune Technologies Inc. (formerly MC Partners Inc.)
Condensed Consolidated Statements of Operation and Comprehensive Loss
(Expressed in Canadian Dollars - unaudited)

	Nine months ended August 31, 2013	Nine months ended August 31, 2012	Three months ended August 31, 2013	Three months ended August 31, 2012
Expenses	$	$	$	$
Administrative and general office	3,260	1,412	(2,261)	-
Accounting and audit fees	25,575	8,466	3,137	2,260
Bank charges and interest	764	-	715	-
Consulting fees	70,530	-	70,250	-
Depreciation	435	-	435	-
Foreign exchange	877	-	877	-
Insurance	440	-	440	-
Investor relations and marketing	708	-	708	-
Legal fees	47,837	-	4,189	-
Research and development	18,146	-	18,146	-
Share-based payment expense	266,059	36,500	266,059	36,500
Sponsorship fees	24,500	-	-	-
Transfer agent, listing and filing fees	30,163	14,239	4,528	1,550
Travel and entertainment	5,255	1,069	4,688	175
Total income (expenses)	(494,549)	(61,686)	(371,911)	(40,485)
Other income (expenses)				
Interest income	2,728	-	2,728	-
Net loss and comprehensive loss for the period	$ (491,821)	$ (61,686)	$ (369,183)	$ (40,485)
Basic and diluted loss per share	$ (0.04)	$ (0.03)	$ (0.03)	$ (0.01)
Weighted average common shares outstanding - diluted	12,672,727	2,138,182	15,432,432	4,900,000

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

bioMmune Technologies Inc. (formerly MC Partners Inc.)
Condensed Consolidated Statements of Operation and Comprehensive Loss
(Expressed in Canadian Dollars - unaudited)

	Common Shares				
	Number of Shares	**Amount**	**Reserve**	**Deficit**	**Total Shareholders' Equity**
		$	**$**	**$**	**$**
Balance, November 30, 2011	2,000,000	100,000	-	(14,447)	85,553
Issue of common shares	5,000,000	500,000	-	-	500,000
Share issuance costs	-	(137,880)	26,335	-	(111,545)
Share-based payment	-	-	36,500	-	36,500
Net loss for the period	-	-	-	(61,686)	(61,686)
Balance, August 31, 2012	7,000,000	462,120	62,835	(76,133)	448,822
Share issuance costs	-	(24,714)	-	-	(24,714)
Net loss for the period	-	-	-	(30,399)	(30,399)
				-	
Balance, November 30, 2012	7,000,000	437,406	62,835	(106,532)	393,709
Issue of common shares for cash	10,000,000	1,500,000	-	-	1,500,000
Share issuance costs	-	(107,238)	-	-	(107,238)
Issue of common shares re asset acquisition	5,600,000	840,000	-	-	840,000
Share-based payment	-	-	266,059	-	266,059
Net loss for the period	-	-	-	(491,821)	(491,821)
Balance, August 31, 2013	22,600,000	2,670,168	328,894	(595,343)	2,400,709

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

bioMmune Technologies Inc. (formerly MC Partners Inc.)
Condensed Consolidated Statements of Cash Flows
(Expressed in Canadian Dollars - unaudited)

	Nine months ended August 31,		Three months ended August 31,	
	2013	**2012**	**2013**	**2012**
Cash provided by (used in):				
Operating activities:				
Net profit (loss) for the period	$ (491,821)	$ (61,686)	$ (369,183)	$ (40,601)
Items not involving cash				
Depreciation expense	435	-	435	-
Share-based payments	266,059	36,500	266,059	36,500
Changes in non-cash working capital:				
Receivables	(16,484)	-	(9,281)	-
Prepaid expenses	(10,904)	33,377	(9,910)	-
Accounts payable and accrued liabilities	(11,387)	(6,629)	(35,393)	1,517
	(264,102)	1,562	(157,273)	(2,584)
Investing activities:				
Cash acquired on acquisition of subsidiary	(10,544)	-	-	-
Computer equipment and software	(2,108)	-	(2,108)	-
Intangible assets	(171,972)	-	-	-
			-	
Purchase of short-term investment	(1,336,590)	-	(1,336,590)	-
	(1,521,215)	-	(1,338,698)	-
Financing activities:				
Shares issued for cash	1,500,000	500,000	-	-
Share issuance costs	(107,237)	111,545	-	-
	1,392,763	388,455	-	-
Net change in cash and cash equivalents	(392,554)	390,017	(1,495,971)	(2,584)
Cash and cash equivalents, beginning of period	417,794	61,253	1,521,211	453,854
Cash and cash equivalents, end of period	$ 25,240	$ 451,270	$ 25,240	$ 451,270

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

1. NATURE OF OPERATIONS AND GOING CONCERN

bioMmune Technologies Inc. (formerly MC Partners Inc.) (the "Company") was incorporated on January 28, 2011 pursuant to the *Business Corporations Act*, British Columbia, under the name MC Partners Inc. as a capital pool company as defined by Policy 2.4 (the "CPC" Policy") of the TSX Venture Exchange (the "Exchange"). On May 24, 2013, the Company acquired all of the issued and outstanding shares of bioMmune AdvancedTechnologies Inc. (formerly bioMmune Technologies Inc.) ("BAT"), a private company (incorporated on July 5, 2012) formed to commercially exploit a number of patents and patent applications that surround three technologies (the "Acquisition" and the "Intellectual Property" respectively). The Acquisition constituted the Company's Qualifying Transaction pursuant to the CPC Policy of the Exchange. On May 22, 2013, the Company changed its name to bioMmune Technologies Inc. and BAT changed its name to bioMmune Advanced Technologies Inc. The Company is a Tier 2 Research and Development Issuer engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system, trading on the Exchange under the trading symbol "IMU".

The Company's registered office is Suite 300 – 576 Seymour Street, Vancouver, BC, Canada.

The Company has not generated any revenues and has incurred losses of $488,811 since inception. The Company expects to spend a significant amount of capital to fund research and development and on further laboratory and animal studies. As a result, the Company expects that its operating expenses will increase significantly and, consequently, will require significant revenues to become profitable. Even if the Company does become profitable, it may not be able to sustain or increase profitability on a quarterly or annual basis. The Company cannot predict when, if ever, it will be profitable. There can be no assurances that the Intellectual Property of the Company, or other technologies it may acquire, will meet applicable regulatory standards, obtain required regulatory approvals, be capable of being produced in commercial quantities at reasonable costs, or be successfully marketed. The Company plans to undertake additional laboratory and animal studies with respect to the Intellectual Property and there can be no assurance that the results from such studies or trials will result in a commercially viable product or will not identify unwanted side effects.

These condensed consolidated interim financial statements have been prepared under the assumptions of a going concern, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The Company's ability to maintain its existence is dependent upon the continuing support of its creditors and its success in obtaining new equity financing for its ongoing operations. Financing options available to the Company include public equity financings and loans. Realization values may be substantially different from carrying values, as shown in these condensed consolidated interim financial statements, should the Company be unable to continue as a going concern.

The condensed consolidated interim financial statements of the Company were authorized for issue by the Board of Directors on October 25, 2013.

2. BASIS OF PRESENTATION

(a) Statement of compliance

These condensed consolidated interim financial statements are unaudited and have been prepared using accounting policies consistent with International Financial Reporting Standards ("IFRS") and in accordance with International Accounting Standard ("IAS") 34 – "Interim Financial Reporting" as issued by the International Accounting Standards Board ("IASB").

These condensed consolidated interim financial statements do not include the information required for full annual financial statements. The condensed consolidated interim financial statement should be read in conjunction with the Company's audited annual financial statements as at and for the year ended November 30, 2012.

(b) Basis of measurement

The condensed consolidated interim financial statements have been prepared on a historical cost basis, except for financial instruments classified as fair value through profit or loss ("FVTPL"), which are stated at their fair values. In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

(c) Functional and presentation currency

These condensed consolidated interim financial statements are presented in Canadian dollars, which is the Company's functional currency.

(d) Use of estimates and judgments

The preparation of condensed consolidated interim financial statements in compliance with IFRS requires management to make judgments and estimates of effects of uncertain future events on the carrying amounts of the Company's assets and liabilities at the end of the reporting date. Actual results may differ from those estimates as the estimation process is inherently uncertain. Actual future outcomes could differ from present estimates and judgments, potentially having material future effects on the Company have condensed consolidated interim financial statements. Management has applied judgment in determining the allocation of value of the net assets of BAT (note 4), and in assessing that there is no impairment of the Company's intangible assets.

3. SIGNIFICANT ACCOUNTING POLICIES

These condensed consolidated interim financial statements have been prepared in accordance with the accounting policies described in Note 3 of the Company's audited annual financial statements as at and for the year ended November 30, 2012.

(Expressed in Canadian Dollars - unaudited)

4. SHORT-TERM INVESTMENT

Short-term investments consist of a term deposit. As at August 31, 2013, the Company has a short-term deposit of $1,334,000 of principal (November 30, 2012: $nil) and $2,590 of accrued interest due on June 4, 2014 (November 30, 2012: $nil) with an annual yield of 1.35%.

5. ASSET ACQUISITION

On May 24, 2013, the Company acquired all of the issued and outstanding common shares of BAT in exchange for 5,600,000 common shares of the Company at a deemed price of $0.15 per common share. The cost of the Acquisition is based on the fair value of the consideration given.

As BAT was not considered to be an acquired business under accounting guidance, the Acquisition was accounted for as an asset acquisition. The purchase consideration is $840,000 and the purchase price allocation relating to the Acquisition has been accounted for as follows:

Cash	$	10,544
Accounts receivable		349
Prepaid expenses		994
Intangible assets		872,516
Accounts payable and accrued liabilities		(44,403)
Net asset value of BAT	$	840,000

The difference between the purchase consideration and the fair values of BAT's net assets as at May 24, 2013 has been assigned to intangible assets ($854,827). Accordingly, the $854,827 was added to BAT's intangible assets carrying value of $17,689 as at May 24, 2013, for a total of $872,516 as above.

6. INTANGIBLE ASSETS

		2013
Balance, November 30, 2012	$	-
Additions		1,172,516
Balance, August 31, 2013	$	1,172,516

a) On October 3, 2012, BAT entered into a patent assignment agreement ("UBC Agreement") with the University of British Columbia ("UBC"), whereby UBC assigned certain patents and patents pending and associated written materials to BAT in exchange for 600,000 BAT common shares (issued) with a fair value of $4,332;

b) On October 18, 2012, BAT entered into a patent assignment agreement with various individuals (the "Inventors") whereby the Inventors assigned certain patents and patents

6. INTANGIBLE ASSETS (Continued)

pending and associated written materials to BAT in exchange for 1,850,000 BAT common shares (issued) with a fair value of $13,357;

c) On May 24, 2013, the Company acquired BAT (note 4) and the difference between the purchase consideration and the fair values of BAT's net assets has been assigned to intangible assets ($854,827); and

d) Pursuant to the terms of the UBC Agreement, the Company is to pay UBC an assignment fee of $300,000, payable in two installments as follows:

   i. $150,000 due within 5 days of the Acquisition (paid); and
   ii. $150,000 due six months after the Acquisition (i.e. November 24, 2013).

7. SHARE CAPITAL

(a) Authorized:

The authorized share capital of the Company consists of an unlimited number of common shares without par value.

(b) Common shares:

During the nine months ended August 31, 2013, the Company:

- Issued 5,600,000 common shares at $0.15 per common share in relation to the Acquisition (note 4); and

- Completed a non-brokered private placement of 10,000,000 units at a price of $0.15 per unit for gross proceeds of $1,500,000 (the "Financing"). Share issuance costs totaled $107,238 for net proceeds of $1,392,762. Each unit consisted of one share and one transferable share purchase warrant of the Company (the "Warrant"). Each Warrant entitles the holder to purchase one additional share in the Company at a price of $0.25 for a period of 12 months from the completion of the private placement and is subject to an exercise acceleration clause. Under the acceleration clause, which the Company may exercise once the private placement units are free of the resale restrictions and if the shares of the Company are trading at or above a volume weighted average price of $0.40 for more than 20 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the warrant holders via a news release. Pursuant to the terms of the Financing, the Company paid to Haywood Securities Inc. a finders' fee of $100,020 and issued 1,000,200 finders warrants (each a "Finder Warrant"). Each Finder Warrant is exercisable into one common share of the Company for a period of 12 months at a price of $0.25. All securities are subject to a hold period expiring on September 25, 2013.

(Expressed in Canadian Dollars - unaudited)

7. SHARE CAPITAL (Continued)

(b) Common Shares (Continued)

During the year ended November 30, 2012, the Company issued 5,000,000 common shares at a price of $0.10 per share for gross proceeds of $500,000. Share issuance costs totaled $162,594 for net proceeds of $337,406.

(c) Escrowed shares

As at August 31, 2013, the Company has 6,930,000 (2012: 2,100,000) common shares held in escrow. These shares will be released from escrow pro rata to the shareholders as to 15% every six months after May 24, 2013 for a period of 30 months.

(d) Stock options

During the year ended November 30, 2012, the Company adopted a stock option plan, which provides that the Board of Directors may from time to time, in its discretion, and all in accordance with the Exchange requirements, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares exercisable for five years from the date of grant.

A summary of the Company's outstanding stock options and changes during the periods then ended is as follows:

	Number of Options Outstanding	Weighted Average Exercise Price ($)
Balance November 30, 2011	-	-
Granted	700,000	0.10
Balance, November 30, 2012	700,000	0.10
Granted	1,325,000	0.23
Balance, August 31, 2013	2,025,000	0.185

On May 3, 2012, the Company granted 700,000 stock options to its officers and directors. The options are exercisable at a price of $0.10 per share. The options will be exercisable for a period of five years from the grant date. The fair value of the stock options granted was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: risk free interest rate of 1.56%; expected dividend rate of 0%; expected volatility of 100%; and expected life of 5 years. The fair value of these options was calculated at $36,500, which was recognized as share-based payments.

(Expressed in Canadian Dollars - unaudited)

7. SHARE CAPITAL (Continued)

(d) Stock Options (Continued)

On June 19, 2013, the Company granted 1,325,000 stock options to its officers and directors. The options are exercisable at a price of $0.23 per share for a period of five years from the grant date. The fair value of the stock options granted was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: risk free interest rate of 1.40%; expected dividend rate of 0%; expected volatility of 129%; and expected life of 5 years. The fair value of these options was calculated at $266,059, which was recognized as share-based payments.

Companies are required to utilize an estimated forfeiture rate when calculating the expense for the reporting period. Based on the best estimate, management applied the estimated forfeiture rate of 0% in determining the expense recorded in the accompanying condensed consolidated interim statements of operations.

The options outstanding and exercisable at August 31, 203 are as follows:

Number Outstanding	Weighted Average Exercise Price ($)	Weighted Average Remaining Contractual Life (Years)
700,000	0.10	3.75
1,325,000	0.23	4.80
2,025,000	0.19	4.43

(e) Agent options

A summary of the Company's outstanding agent options and changes during the periods then ended is as follows:

	Quantity	Weighted Average Exercise Price
Balance, November 30, 2011	**-**	**$ -**
Issued	500,000	$ 0.12
Balance, November 30, 2012 and August 31, 2013 Outstanding and exercisable	**500,000**	**$ 0.12**

In connection with the Company's IPO, the Company granted agent options to purchase 500,000 common shares at a price of $0.10 per share, expiring May 3, 2014 and with a fair value of $26,335.

(Expressed in Canadian Dollars - unaudited)

7. SHARE CAPITAL (Continued)

(e) Agent options (Continued)

The fair value of the agent options is estimated using the Black-Scholes option pricing model with the following weighted average assumptions: risk free interest rate of 1.30%; expected dividend yield of 0%; expected volatility of 100%; and expected life of 2 years. Management applied the estimated forfeiture rate of 0%.

The expected volatility used in calculating the fair value of stock options and agent options granted is determined based on the historical share price of peer group companies over the estimated lives of the agent options and stock options.

(f) Share purchase warrants

A summary of the Company's outstanding share purchase warrants and changes during the periods then ended is as follows:

	Quantity		Weighted Average Exercise Price
Balance, November 30, 2011 and 2012	**-**	**$**	**-**
Issued (*)	10,000,000		0.25
Balance, August 31, 2013	**10,000,000**	**$**	**0.25**

* Exercisable on or before May 24, 2014

(g) Finders' warrants

A summary of the Company's outstanding finders' warrants and changes during the periods then ended is as follows:

	Quantity		Weighted Average Exercise Price
Balance, November 30, 2011 and 2012	**-**	**$**	**-**
Issued (*)	1,000,200	$	0.25
Balance, August 31, 2013	**1,000,200**	**$**	**0.25**

* Exercisable on or before May 25, 2014 and resulting shares issued subject to a hold period expiring on September 25, 2013

The remaining contractual life of the finders' warrants is 0.73 (2012: N/A) years.

(Expressed in Canadian Dollars - unaudited)

8. CAPITAL RISK MANAGEMENT

The Company's objective when managing capital is to safeguard the Company's ability to continue as a going concern in order to pursue the development of any identified business opportunities and to maintain a flexible capital structure for the benefit of its stakeholders.

The Company includes equity, comprised of issued share capital, reserves and deficit in the definition of capital.

The Company manages the capital structure and makes adjustments to it in light of changes in the economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares, enter into joint venture arrangements, acquire or dispose of assets, or adjust the amount of cash.

The Board of Directors does not establish quantitative return on capital criteria for management but rather promotes year over year sustainable growth. The Company is not subject to externally imposed capital requirements. There were no changes in the Company's approach to capital management during the six months ended August 31, 2013.

9. SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS

	2013	**2012**
	$	**$**
Shares issued for business acquisition	840,000	-
Intangible assets in accounts payable	150,000	-

10. RELATED PARTY TRANSACTIONS

The following directors and/or senior officers transacted with the Company in the reporting period. The terms and conditions of the transactions with key management personnel and their related parties were no more favourable than those available, or which might reasonably be expected to be available, on similar transactions to non-key management personnel related entities on an arm's length basis. The following is a summary of related party transactions that occurred during the nine months ended August 31, 2013 and during the year ended November 30, 2012:

Key Management Compensation:

Services provided by:		August 31, 2013	August 31, 2012
RBH Consulting Inc.	a)	24,000	-
Judi Dalling	b)	16,250	-
Cydweli Consultants Inc.	c)	15,000	-
John Morgan	d)	280	-
		55,530	-

10. RELATED PARTY TRANSACTIONS (Continued)

a) RBH Consulting Inc. is a privately held corporation controlled by a director who provided consulting services to the Company.
b) Judi Dalling, the CFO of the Company, provided consulting services to the Company.
c) Cydweli Consultants Inc. is a privately held corporation controlled by an officer who provided consulting services to the Company.
d) John Morgan, formerly a director of the Company, provided consulting services to the Company.

Other related party transactions include:

- On May 24, 2013, as part of the Acquisition, a director of the Company acquired direct ownership of 1,325,000 common shares of the Company and control and direction over an additional 1,325,000 common shares, collectively representing approximately 11.73% of the Company's issued and outstanding common shares;

- Administrative and general office expenditures and listing fees of $24,687 (2012: $846) for reimbursements of same were paid to directors and officers; and

As at August 31, 2013, net due to related parties was $1,500 (2012: $110); this balance is included in accounts payable and accrued liabilities and prepaid expenses without interest or stated terms of repayment.

11. COMMITMENTS

Effective June 1, 2013, the Company entered into consulting agreements as follow:

i. Consulting agreement with RBH Consulting Inc., a company fully owned by an officer of the Company, to provide consulting services to the Company for a fee of $96,000 per year;

ii. Consulting agreement with Cydweli Consultants Inc., a company fully owned by an officer of the Company, to provide consulting services to the Company for a fee of $60,000 per year; and

iii. Consulting agreement with Judi Dalling, CFO of the Company, to provide consulting services to the Company for a fee of $65,000 per year.

In addition to the fees set forth above, incentive bonuses may be granted at the discretion of the Board of Directors.

(Expressed in Canadian Dollars - unaudited)

12. FINANCIAL INSTRUMENTS

(a) Fair Values

Financial instruments recognized at fair value on the consolidated statement of financial position must be classified in one of the following three fair value hierarchy levels:

Level 1 – measurement based on quoted prices (unadjusted) observed in active markets for identical assets or liabilities;
Level 2 – measurement based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability; or
Level 3 – measurement based on inputs that are not observable (supported by little or no market activity) for the asset or liability.

Assets and liabilities measured at fair value on a recurring basis were presented on the Company's consolidated statements of financial position are as follows:

	Fair Value Measurements Using		
As at August 30, 2013	**Quoted prices in active markets for identical instruments (Level 1) $**	**Significant other observable inputs (Level 2) $**	**Significant unobservable inputs (Level 3) $**
Cash and cash equivalents	25,240	-	-
Short term investments	1,336,590	-	-
Total	1,361,830	-	-

	Fair Value Measurements Using		
As at November 30, 2012	**Quoted prices in active markets for identical instruments (Level 1) $**	**Significant other observable inputs (Level 2) $**	**Significant unobservable inputs (Level 3) $**
Cash and cash equivalents	417,794	-	-
Short term investments	-	-	-
Total	417,794	-	-

The fair values of other financial instruments, which include other receivable, other assets, bank indebtedness, accounts payable and accruals and due to related parties, approximate their carrying values due to the relatively short-term maturity of these instruments.

(b) Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company limits its exposure to credit loss by placing its cash and cash equivalents with high credit quality financial institutions. The carrying amount of financial assets represents the maximum credit exposure.

(Expressed in Canadian Dollars - unaudited)

11. FINANCIAL INSTRUMENTS (Continued)

(c) Liquidity Risk

Liquidity risk is managed by ensuring sufficient financial resources are available to meet obligations associated with financial liabilities. The following table is based on the contractual maturity dates of financial assets and the earliest date on which the Company can be required to settle financial liabilities.

Contractual maturity analysis is as follows:

	Less than 3 months	3-12 months	1-5 years	Longer than 5 years	Total
	$	$	$	$	$
August 30, 2013					
Accounts payable and accrued liabilities	162,698	-	-	-	162,698
	162,698	-	-	-	162,698
November 30, 2012					
Accounts payable and accrued liabilities	24,085	-	-	-	24,085
	24,085	-	-	-	24,085
August 30, 2012					
Accounts payable and accrued liabilities	3,488	-	-	-	3,488

11. EVENTS AFTER THE REPORTING PERIOD

a) On October 22, 2013, 175,000 stock options were exercised at a price of $0.10 per common share. Following the exercise of the stock options, the Company has 1,675,000 stock options outstanding and 22,950,000 common shares issued and outstanding.

b) On October 17, 2013, 175,000 stock options were exercised at a price of $0.10 per common share.

c) On September 24, 2013, the company granted 150,000 stock options to a director of the Company at an exercise price of $0.20 per common share. The options are exercisable for five years from date of grant.